Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift? (Record no. 2932)

MARC details
000 -LEADER
fixed length control field	01200nam a22002537a 4500
005 - DATE AND TIME OF LATEST TRANSACTION
Date and Time of Latest Transaction	20220616115637.0
100 ## - AUTHOR
Author	Koffas A
100 ## - AUTHOR
Author	Mak L Y
100 ## - AUTHOR
Author	Gill U S
100 ## - AUTHOR
Author	et al
245 ## - TITLE
Title	Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift?
257 ## - COUNTRY OF ORIGIN
Country of origin	U.K. & Hong Kong
264 ## - PUBLICATION
Place of publication	Basel SWI
Name of publisher	MDPI
Date of publication	2022
300 ## - PHYSICAL DESCRIPTION
Physical description	12p.
490 ## - SERIES
Series title	Viruses
Volume	Vol. 4 (5)
546 ## - LANGUAGE
Language	Available in: English
653 ## - SUBJECT
Subject	Treatment & research: Medical treatment
856 ## - Web Address
URL	https://www.mdpi.com/1999-4915/14/5/900
Link text	Link to open access article
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type	Online journal/article
520 ## - SUMMARY, ETC.
Contents:	To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.<br/><br/>Related terms Hep B, HBV.

Holdings
Withdrawn status	Lost status	Source of classification or shelving scheme	Damaged status	Loan status	Home library	Current library	Shelving location	Date acquired	Total Checkouts	Date last seen	Price effective from	Koha item type
		Other/Generic Classification Scheme		Available	Library	Library	Online	15/05/2022		15/05/2022	15/05/2022	Online journal/article